Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

References

• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2013 Available from: http://www.goldcopd.org/Accessed on January 8, 2014
   Google Scholar
• CazzolaMMateraMGLong-acting bronchodilators are the first-choice option for the treatment of stable COPDChest2004125191114718412
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA)Seebri Breezhaler (glycopyrronium bromide: summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdfAccessed June 25, 2013
   Google Scholar
• Novartis GlobalNovartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU [press release]Basel, SwitzerlandNovartis2012 [October 1]. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1645116.shtmlAccessed 22 November, 2012
   Google Scholar
• European Medicines Agency (EMA)Bretaris Genuair (aclidinium bromide): summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002706/WC500132732.pdfAccessed June 25, 2013
   Google Scholar
• European Medicines Agency (EMA)Eklira Genuair (aclidinium bromide): summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002211/WC500132661.pdfAccessed June 25, 2013
   Google Scholar
• US Food and Drug Administration (FDA)Tudorza Pressair (aclidinium bromide): US prescribing information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdfAccessed June 25, 2013
   Google Scholar
• BeehKMSinghDDiSLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograAOwenRLassenCKramerBLong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSAmosCOwenRLassenCIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• VogelmeierCRamos-BarbonDJackDIndacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumRespir Res20101113520920365
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensECombining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptomsRespir Med20101047995100420303247
   PubMed Web of Science ®Google Scholar
• VinckenWAn update of bronchodilator treatment of chronic obstructive pulmonary disease (COPD) [abstract]Ann Respir Med20101116
   Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• MaltaisFBeckEWebsterDFour weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]Eur Respir J2010365557
   Google Scholar
• TashkinDPLittnerMAndrewsCPTomlinsonLRinehartMDenis-MizeKConcomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trialRespir Med2008102447948718258423
   PubMed Web of Science ®Google Scholar
• TashkinDPPearleJIezzoniDVargheseSTFormoterol and tiotropium compared with tiotropium alone for treatment of COPDCOPD200961172519229704
   PubMedGoogle Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J2013124261484149423722616
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2010 Available from: http://www.goldcopd.org/Accessed November 23, 2013
   Google Scholar
• Clinicaltrials.gov identifier NCT1604278 http://clinicaltrials.gov/show/NCT1604278Accessed on 16th January 2014
   Google Scholar
• MozzicatoPMedDRAAn Overview of the Medical Dictionary for Regulatory ActivitiesPharm Med2009236575
   Google Scholar
• WitekTJJrMahlerDAMinimal important difference of the transition dyspnoea index in a multinational clinical trialEur Respir J200321226727212608440
   PubMed Web of Science ®Google Scholar
• JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• [No authors listed]In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study GroupChest19941055141114198181328
   PubMed Web of Science ®Google Scholar
• [No authors listed]Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study GroupChest19971126151415219404747
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyEur Respir J10312013 [Epub ahead of print]
   Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• YawnBPKaplanACo-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation?Prim Care Respir J200817419920518338090
   PubMedGoogle Scholar
• CalverleyPMRennardSIWhat have we learned from large drug treatment trials in COPD?Lancet2007370958977478517765527
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAPImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363
   PubMed Web of Science ®Google Scholar
• VogelmeierCBatemanEPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol – fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• PriceDYawnBBrusselleGRossiARisk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrim Care Respir J20132219210023135217
   PubMedGoogle Scholar